Latest Stock Research & Market Analysis
Search All Research, Articles & Stock Profiles
ASX Stock Research
[BUY] Aristocrat Leisure (ASX: ALL) – A Billion-Dollar Interactive Path
Aristocrat Leisure (ASX: ALL) at A$61.40, charting a path to US$1bn in Interactive revenue by FY29 as iGaming and iLotteries scale. Buy, around 14% upside.
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
[BUY] Collins Foods (ASX: CKF) – Qld and WA Exposure Outweighs the Wage Cost Squeeze
Collins Foods (ASX: CKF) at A$8.27 trades ~20% below its historical PE. Qld/WA exposure plus a kiosk rollout offset wage pressure. 29% upside, Buy.
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
[BUY] Collins Foods (ASX: CKF) – Qld and WA Exposure Outweighs the Wage Cost Squeeze
Collins Foods (ASX: CKF) at A$8.27 trades ~20% below its historical PE. Qld/WA exposure plus a kiosk rollout offset wage pressure. 29% upside, Buy.
Global Macro and Market Research
Why the Iran Oil Shock Points to More RBA Hikes, Not Fewer
The default narrative around the Iran conflict and the oil spike that has followed it is that it is bad news, full stop. Higher energy costs feed into inflation, dent consumer spending, and put pressure on central banks to either hold tight or cut rates to cushion the...
Supply Shock to Knock the RBA Off the “Narrow Path” and Into the Rough
We held a positive outlook on the Australian macro earlier this year, but that view has been substantially undermined by the war in Iran. Surging fuel prices, rising interest rates, and the flow-on effects to cost-of-living pressures are now the dominant themes...
Gold Investment Primer and Why Gold Matters for Investors
The Gold Market and Why It Matters for Investors Gold is one of the most misunderstood assets in modern finance. It generates no cash flow, pays no dividend, and has limited industrial use compared to other metals. Yet it has preserved purchasing power across...
Global Stock Research
[BUY] Eli Lilly (LLY): Foundayo Reframes the Oral GLP-1 Story
LLY Buy with ~37% upside to ~US$1,283. 1Q26 EPS US$8.55 beat US$6.77, 2026 guide raised to US$82-85bn. Foundayo oral GLP-1 hits 8k prescribers in 3 weeks, 80% new incretin patients.
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the Street, automotive gross margins running well ahead of forecast, and energy storage...
[BUY] Corvus Pharmaceuticals (CRVS) – Novel and Differentiated Contender in Auto-Immune and Hematology
Corvus Pharmaceuticals has developed soquelitinib, a first-in-class oral ITK inhibitor targeting moderate-to-severe atopic dermatitis and relapsed/refractory peripheral T cell lymphoma. We initiate at Buy with a 12-month price target of $40.
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the...
[BUY] Corvus Pharmaceuticals (CRVS) – Novel and Differentiated Contender in Auto-Immune and Hematology
Corvus Pharmaceuticals has developed soquelitinib, a first-in-class oral ITK inhibitor targeting moderate-to-severe atopic dermatitis and relapsed/refractory peripheral T cell lymphoma. We initiate at Buy with a 12-month price target of $40.
Region & Industry Outlook
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
ASX Announcement
Commonwealth Bank of Australia (ASX: CBA) – CBAPJ Hybrid Security Suspension and Removal
Commonwealth Bank of Australia has announced the immediate suspension of its CommBank PERLS XIII Capital Notes (ASX Code: CBAPJ) from quotation, effective as of 8 October 2026. The suspension stems from an imminent redemption of the security, which will trigger the...
MAAS Group Holdings (ASX: MGH) – MAAS Group Responds to Price Query
Maas Group Holdings (ASX: MGH) experienced a sharp and sudden sell-off, falling from $6.39 to $4.50 in a single session, representing a decline of approximately 29 percent. The scale of this move caught the attention of the Australian Securities Exchange, which...
Fortescue (ASX: FMG) – Fortescue September 2026 Quarterly Results
Fortescue Ltd's net debt position deteriorated significantly in the September quarter, climbing to US$2.8 billion from US$0.9 billion at the end of June, marking a material shift in the company's financial position. The increase reflects the combined impact of the...
MAAS Group Holdings (ASX: MGH) – MAAS Group Responds to Price Query
Maas Group Holdings (ASX: MGH) experienced a sharp and sudden sell-off, falling from $6.39 to $4.50 in a single session, representing a decline of approximately 29 percent. The...
Fortescue (ASX: FMG) – Fortescue September 2026 Quarterly Results
Fortescue Ltd's net debt position deteriorated significantly in the September quarter, climbing to US$2.8 billion from US$0.9 billion at the end of June, marking a material shift...
Top Stock Reports
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000